Advanced bladder cancer: New agents and new approaches. A review

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 1, 2013, Pages 9-16

  Volpe, Andrea ^a   Racioppi, Marco ^a   D'Agostino, Daniele ^a   D'Addessi, Alessandro ^a   Marangi, Francesco ^a   Totaro, Angelo ^a   Pinto, Francesco ^a   Sacco, Emilio ^a   Battaglia, Sandra ^b   Chiloiro, Giuditta ^a   Bassi, Pier Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bladder cancer; Chemotherapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EISAI; ERIBULIN; FLUOROURACIL; GALLIUM NITRATE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IXABEPILONE; JAVLORS; LONAFARNIB; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; RPI 4610; TACEDINALINE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VINFLUNINE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CA; COLORECTAL CANCE; COLORECTAL CANCER; COMORBIDITY; CONFUSION; CONSTIPATION; CYSTECTOMY; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GOLD STANDARD; HEAD AND NECK CANCER; HEADACHE; HISTONE ACETYLATION; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; META ANALYSIS; MICROMETASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NON SMALL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PELVIS LYMPH NODE; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REFERENCE DATABASE; RESPIRATORY FAILURE; REVIEW; SALVAGE THERAPY; SENSORY NEUROPATHY; SEPSIS; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; URINARY BLADDER NEOPLASMS;

EID: 84873993948     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.03.022     Document Type: Review

References (63)

1. Jemal A. Cancer Statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Cancer Incidence in Five Continents. IARC Scientific Publication 155 2002, Vol. VIII. International Agency for Research on Cancer (IARC), IARC Press, Lyon, France.
3. Bassi P., Ferrante G.D., Piazza N., et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort. J Urol 1999, 161:1494-1497.
4. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
5. Dalbagni G., Genega E., Hashibe M., et al. Cystectomy for bladder cancer: A contemporary series. J Urol 2001, 165:1111-1116.
6. Ghoneim M.A., el-Mekresh M.M., el-Baz M.A., et al. Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol 1997, 158:393-399.
7. Hussain S.A., James N.D. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003, 4:489-497.
8. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403-407.
9. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989, 64:2448-2458.
10. Harker W.G., Meyers F.J., Freiha F.S., et al. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985, 3:1463-1470.
11. Roth B.J., Bajorin D.F. Advanced bladder cancer: The need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) world. J Urol 1995, 153:894-900.
12. Sher H.I., Shipley W.U., Herr H.W. Cancer of the Bladder 1997, Lippincott-Raven Publishers, Philadelphia (PA).
13. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8:1050-1055.
14. Troner M., Birch R., Omura G.A., et al. Phase III comparison of cisplatin alone vs. cisplatin, doxorubicin, and cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group trial. J Urol 1987, 137:660-662.
15. Boutan-Laroze A., Mahjoubi M., Droz J.P., et al. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur J Cancer 1991, 27:1690-1694.
16. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992, 10:1066-1073.
17. Fossa S.D., Sternberg C., Scher H.I., et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 1996, 74:1655-1659.
18. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
19. Cohen M.H., Rothmann M. Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol 2001, 19:1229-1231.
20. Chitambar C.R. Apoptotic mechanisms of gallium nitrate: Basic and clinical investigations. Oncology (Williston Park) 2004, 18:39-44.
21. McCaffrey J.A., Hilton S., Mazumdar M., et al. Phase II randomized trial of gallium nitrate plus fluorouracil vs. methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol 1997, 15:2449-2455.
22. Crawford E.D., Saiers J.H., Baker L.H., et al. Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology 1991, 38:355-357.
23. Seidman A.D., Scher H.I., Heinemann M.H., et al. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 1991, 68:2561-2565.
24. Seligman P.A., Crawford E.D. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 1991, 83:1582-1584.
25. Einhorn L.H., Roth B.J., Ansari R., et al. Phase II trial of vinblastine, ifosfamide and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994, 12:2271-2276.
26. Dreicer R., Propert K.J., Roth B.J., et al. Vinblastine, ifosfamide, and gallium nitrate-an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892). Cancer 1997, 79:110-114.
27. Witte R.S., Elson P., Bono B., et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997, 15:589-593.
28. Pagliaro L.C., Millikan R.E., Tu S.M., et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: A feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 2002, 20:2965-2970.
29. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating 2 dosing schedules. Cancer 2000, 88:1671-1678.
30. Sweeney C.J., Williams S.D., Finch D.E., et al. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999, 86:514-518.
31. Krege S., Rembrink V., Borgermann C., et al. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: A phase 2 study. J Urol 2001, 165:67-71.
32. Dodd P.M., McCaffrey J.A., Hilton S., et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000, 18:840-846.
33. Paz-Ares L., Tabernero J., Moyano A., et al. Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a Phase III trial. Ann Oncol 1998, 9:292-296.
34. Sweeney C.J., Roth B.J., Kabbinavar F.F., et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006, 24:3451-3457.
35. Galsky M.D., Mironov S., Iasonos A., et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007, 25:265-270.
36. von der Maase H., Lehmann J., Gravis G., et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 2006, 17:1533-1538.
37. Dreicer R., Li S., Manola J., et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the eastern cooperative oncology group. Cancer 2007, 110:759-763.
38. Winquist E., Vokes E., Moore M.J., et al. A phase II study of oxaliplatin in urothelial cancer. Urol Oncol 2005, 23:150-154.
39. Theodore C., Bidault F., Bouvet-Forteau N., et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 2006, 17:990-994.
40. Nyman D.W., Campbell K.J., Hersh E., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005, 23:7785-7793.
41. Kuznetsov G., Towle M.J., Cheng H., et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004, 64:5760-5766.
42. Lonn U., Lonn S., Friberg S., et al. Prognostic value of amplification of cerb-B2 in bladder carcinoma. Clin Cancer Res 1995, 1:1189-1194.
43. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neupositive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007, 25:2218-2224.
44. Inoue K., Slaton J.W., Davis D.W., et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the antivascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000, 6:2635-2643.
45. Sriplakich S., Jahnson S., Karlsson M.G. Epidermal growth factor receptor expression: Predictive value for the outcome after cystectomy for bladder cancer?. BJU Int 1999, 83:498-503.
46. Inoue K., Slaton J.W., Perrotte P., et al. Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000, 6:4874-4884.
47. Basso A.D., Mirza A., Liu G., et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen antitumor activity. J Biol Chem 2005, 280:31101-31108.
48. Doll R.J., Kirschmeier P., Bishop W.R. Farnesyltransferase inhibitors as anticancer agents: Critical crossroads. Curr Opin Drug Discov Devel 2004, 7:478-486.
49. Desrosiers R.R., Cusson M.H., Turcotte S., et al. Farnesyltransferase inhibitor SCH-66336 down-regulates secretion of matrix proteinases and inhibits carcinoma cell migration. Int J Cancer 2005, 114:702-712.
50. Oxford G., Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003, 170:1987-1993.
51. Winquist E., Moore M.J., Chi K.N., et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005, 23:143-149.
52. Theodore C., Geoffrois L., Vermorken J.B., et al. Multicentre EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor and gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005, 41:1150-1157.
53. Rosenberg J.E., von der Maase H., Seigne J.D., et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005, 103:2035-2041.
54. Kobayashi H., Eckhardt S.G., Lockridge J.A., et al. Safety and pharmacokinetic study of RPI. 4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005, 56:329-336.
55. Kouraklis G., Theocharis S. Histone deacetylase inhibitors: A novel target of anticancer therapy. (Review). Oncol Rep 2006, 15:489-494.
56. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005, 40:1-13.
57. Pauer L.R., Olivares J., Cunningham C., et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004, 22:886-896.
58. Kassouf W., Luongo T., Brown G., et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006, 176:787-792.
59. Ding Y., Wang G., Ling M.T., et al. Significance of Id-1 up-regulation and its association with EGFR in bladder cancer cell invasion. Int J Oncol 2006, 28:847-854.
60. Hauser-Kronberger C., Peham K., Grall J., et al. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol 2006, 175:875-880. Discussion 880.
61. Kassouf W., Dinney C.P., Brown G., et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 2005, 65:10524-10535.
62. Rotterud R., Nesland J.M., Berner A., et al. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005, 95:1344-1350.
63. Reicer R., Manola J., Roth B.J., et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: A trial of the Eastern Cooperative Oncology Group. Cancer 2004, 100:1639-1645.